Company Overview
Nano-X Imaging Ltd. operates within the Healthcare sector, specifically focusing on the Medical Devices industry, where it develops commercial-grade tomographic imaging devices equipped with digital X-ray sources alongside teleradiology services and artificial intelligence applications. The company's operational scale is defined by a market capitalization of $159.36M and an annual revenue of $12.30M, supported by a workforce of 165 employees. These financial metrics indicate that the company functions as a mid-cap entity with a revenue base that is relatively small compared to large-cap medical device peers, suggesting a focus on niche technological development rather than mass-market volume dominance. The valuation of $159.36M relative to its $12.30M revenue stream implies that the market is pricing the stock based on future growth potential and intellectual property value rather than current earnings generation, a common characteristic for early-stage biotech and medical technology firms.
Financial Health
The company reported a revenue of $12.30M over the trailing twelve months, yet it recorded a net income of -$55,706,000 and an EBITDA of -$45,925,000, revealing a significant gap between top-line sales and profitability that points to a heavy cost structure driven by research and development expenditures. This financial position is further evidenced by a free cash flow of -$26,877,750, which indicates that the company is burning cash to fund its operations and product development, thereby limiting its immediate financial flexibility without access to external capital markets. The margin analysis shows a gross margin of -98.0%, an operating margin of -413.0%, and a profit margin of 0.0%, all of which collectively demonstrate that the company is currently unprofitable at every operational level, likely due to high fixed costs associated with device manufacturing and AI development. Despite the negative earnings, the company maintains a cash balance of $45.19M against total debt of $7.88M, resulting in a debt-to-equity ratio of 5.03, which suggests a highly leveraged balance sheet where equity is diluted by debt obligations. However, the current ratio stands at 4.14, indicating that the company possesses substantial short-term assets relative to its liabilities, providing a buffer against immediate liquidity crises. Return on Equity is recorded at -34.8% and Return on Assets at -20.0%, metrics that reveal management is currently unable to generate returns on the capital invested in the business, a typical but challenging phase for companies scaling complex medical imaging technologies.
Valuation Assessment
The valuation metrics present a complex picture with a P/E Ratio (TTM) listed as N/A due to the lack of positive earnings, while the Forward P/E is -7.51, implying that analysts are projecting continued losses or that the market is valuing the company on a pre-earnings basis. The price-to-book ratio is 0.96, indicating that the market is currently valuing the company at roughly its net asset value, which offers no premium over the book value of its tangible assets. Alternative valuation measures such as a price-to-sales ratio of 12.95 and an EV/EBITDA of -2.45 suggest that investors are paying a high multiple for every dollar of sales generated, reflecting expectations of future profitability once the company exits its current loss-making phase. The stock's price has fluctuated between a 52-week high of $6.22 and a 52-week low of $2.11, meaning the current share price sits within this historical volatility range, though the specific current price is not provided in the available facts to calculate the exact percentage deviation. The beta value of 1.41 indicates that the stock price is significantly more volatile than the broader market, moving approximately 41% more aggressively than the market index during periods of rising or falling sentiment.
Growth & Income
Nano-X Imaging Ltd. has demonstrated revenue growth of 13.7% year-over-year, while earnings growth is N/A due to the company's lack of profitability, which implies that revenue expansion is not yet translating into bottom-line gains. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that the firm reinvests all available capital and earnings back into research, development, and business scaling rather than distributing income to shareholders. The absence of a dividend yield combined with the current negative earnings growth profile indicates that the company prioritizes long-term product development and market penetration over immediate shareholder returns. The overall growth and income profile is characterized by strong top-line expansion in the medical device sector but a distinct lack of income generation, requiring continuous external financing to sustain operations and fund the 13.7% revenue increase.